The NCCN Kidney Cancer Panel recently revised the subsequent therapy recommendations providing more direction on appropriate subsequent-line options after immuno-oncology (IO) therapy or if the patient is IO therapy-naïve.

Determining treatment regimens for patients with uterine cancer can be challenging. With the availability of increasingly advanced imaging, surgical, and radiation therapy techniques as well as novel systemic therapy options, evidence-based guidance is needed to inform and optimize treatment decisions.

Targeted therapy is a relatively novel treatment approach to pediatric high-grade gliomas. Identifying specific molecular targets with correspondingly effective agents substantially benefits the treatment landscape and broadens therapeutic options in both the adjuvant therapy and recurrent or progressive disease setting.

The incidence of non-AIDS-defining cancers (NADCs) in HIV-positive patients is increasing, and pharmacists should understand and apply pharmacokinetic parameters in order to identify potential interactions and recommend change in therapy or modifications in dosing and/or administration to aid medical oncologists in choosing the right drug at the right dose given at the right time.

It is important for practitioners to understand what factors influence successful stem cell mobilization in preparation for a transplant. They should also be familiar with the agents used in this process.

Oncology pharmacists are vital members of the oncology team with specialized knowledge of anticancer therapy and can help navigate therapeutic interventions, contributing to selection, dosing, monitoring, evaluation, and education of medications to improve oral immune-related adverse event outcomes.

Learn about the challenges associated with the management of transformed indolent lymphomas and the recent advances in management to help you to incorporate novel therapies into routine clinical practice in the appropriate patient population to improve clinical outcomes.

Learn about the recent advances as well as the challenges involved in the diagnosis and management of classical hairy cell leukemia (HCL) and HCL-variant.

This topic will help fill the gap between current and ideal practice by reviewing examples and best practice recommendations that pharmacists can implement in collaboration with interprofessional team members to improve resource utilization, patient safety, and quality of care.